Hopes of a breakthrough in Huntington’s disease have been dashed a number of times, not least this year, but the emergence from stealth mode of a UK biotech backed by Novartis AG's venture arm could provide some optimism down the line for patients with the fatal, inherited neurodegenerative disorder.
LoQus23 Therapeutics has closed a £7m ($9.3m) extended seed round this week after securing financing from the Novartis Venture...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)